Biomarin Pharmaceutical market cap BMRN

Share price times shares outstanding: what the whole company sells for, since 2010.

Biomarin Pharmaceutical is worth $10.8B at the close on Oct 23, 2026, at $55.95 a share.

That is up 4% over the last year and down 26% over five years.

Its highest close in our data was $23.9B in Jul 2015.

Market cap over time

Year	End of year	Low	High	Change
2026 so far	$10.8B	$10B	$13B	−6%
2025	$11.5B	$9.9B	$13.8B	−10%
2024	$12.7B	$12.1B	$18.2B	−30%
2023	$18.2B	$15B	$21.8B	−6%
2022	$19.2B	$13.9B	$20.2B	+19%
2021	$16.2B	$13.5B	$16.8B	+2%
2020	$15.9B	$13.1B	$23.2B	+4%
2019	$15.4B	$11.8B	$17.6B	+3%
2018	$14.9B	$13.4B	$18.3B	−5%
2017	$15.7B	$14.2B	$16.7B	+10%
2016	$14.2B	$11B	$16.1B	−16%
2015	$16.9B	$13.6B	$23.9B	+25%
2014	$13.5B	$8.2B	$13.8B	+37%
2013	$9.8B	$6.4B	$10.8B	+66%
2012	$5.9B	$3.8B	$6.1B	+51%
2011	$3.9B	$2.6B	$4B	+42%
2010	$2.8B	$2.1B	$2.9B	n/a

Companies in Drug Manufacturers - General nearest Biomarin Pharmaceutical's size, closest first, today.

Company	Market cap
BMRNBiomarin Pharmaceutical	$10.8B
CORTCorcept Therapeutics	$9.3B
PTGXProtagonist Therapeutics	$9B
JAZZJazz Pharmaceuticals	$13.9B
TGTXTG Therapeutics	$8.3B
ALKSAlkermes plc.	$7.3B
AMRXAmneal Pharmaceuticals	$6.5B
LGNDLigand Pharmaceuticals	$6.1B
KNSAKiniksa Pharmaceuticals International	$6B
INDVIndivior Pharmaceuticals	$4.1B
ARQTArcutis Biotherapeutics	$3.9B
Peer median	$6.9B